Advisory Research Inc Xencor Inc Transaction History

Advisory Research Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$24.79 - $30.86 $320,683 - $399,204	-12,936 Reduced 61.7%	8,031 $209,000
Q3 2022 Nov 14, 2022	BUY	$24.62 - $32.44 $115,664 - $152,403	4,698 Added 28.88%	20,967 $545,000
Q2 2022 Aug 17, 2022	BUY	$19.74 - $29.01 $321,150 - $471,963	16,269 New	16,269 $445,000
Q4 2019 Feb 11, 2020	SELL	$32.75 - $41.43 $571,684 - $723,202	-17,456 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$33.73 - $46.27 $240,359 - $329,720	-7,126 Reduced 28.99%	17,456 $589,000
Q2 2019 Aug 14, 2019	BUY	$29.6 - $40.93 $727,627 - $1.01 Million	24,582 New	24,582 $1.01 Million

216

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.23B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.